San Francisco Halts New Data Center Construction With 45-Day Moratorium 
Florida Seeks Tougher Meta Rules to Protect Young Users 
Australia Consumer Confidence Plunges as RBA Rate Hike Hits Households 
Nomura Asset Management Targets Global Investors as Japan Markets Gain Appeal 
Gold Prices Fall as Stronger Dollar Weighs on Bullion 
Broadcom, Oracle and SpaceX Seek Billions in Private Debt for AI Expansion 
HSBC Plans Deep UK Wealth Job Cuts in AI Push 
Zcash Privacy Demand Rises as AI Exposes Bitcoin Transactions 
Rapidus Seeks Chip Customers as Japan Pushes 2nm Semiconductor Revival 
Iceland 4x4 Rental Guide: When Do You Really Need Four-Wheel Drive? 
Constellation Brands Beats Q2 Estimates, Buys SpikedAde 
Asian Currencies Steady as Dollar Holds Near 18-Month High 
Asian Stocks Rise as Nasdaq Record Offsets Bond Yield Pressure 
RBI Raises Repo Rate to 5.50% in Hawkish Shift on Inflation Risks 
Samsung, SK Hynix Shares Fall Ahead of Q3 Earnings 
SpaceX Seeks $40 Billion for Nvidia AI Chips 
Add as a preferred source on Google
Merck & Co., Inc. announced it will build a biopharmaceutical raw material production plant in South Korea. It recently signed a memorandum of understanding (MOU) with the Korean Ministry of Trade, Industry and Energy and the local government of Daejeon for the project.
Merck & Co. made the announcement on Wednesday, May 3, and Korea’s MTIE also revealed on the same day that it has signed an investment agreement with Merck Life Science, the national government and the city of Daejeon for the American biopharma company’s plan to build a new bio-processing plant in the country.
According to The Korea Economic Daily, the production facility in Daejeon will supply biopharma raw materials to pharmaceutical and bio companies based in the Asia-Pacific. The Korean national government also promised to provide the necessary support so the project could be successfully implemented.
The trade and industry ministry said that Merck's investment in the country would not just ensure the stable availability of biopharma raw materials in the supply chain but will also significantly contribute to the local economy, as this could also attract more foreign investments.
The city government of Daejeon also noted that the construction of the production facility in the region is also a three-way cooperation that will South Korea’s efforts in achieving balanced regional development. Once completed, the new Merch biopharma manufacturing plant in Daejeon is expected to play an important role as the center for the growth of Korea's bio-industry.
Furthermore, the company’s CEO said the latest investment deal clearly shows Merck's intention to contribute to the development of the country’s bio business sector.
"South Korea is an emerging global leader in the biotech industry, and this Memorandum of Understanding demonstrates Merck's commitment to the region by working closely with the government to better support our customers," Merck Life Science’s executive board member and chief executive officer said in a press release. "The proposed facility would play a vital role in fulfilling demand in the Asia-Pacific region while representing an important hub for further biopharma industry development in South Korea."
